Gastrostat, 100 mg 30 pcs.

Pharmacotherapeutic group: gastroprotective agent.

The ATX code: A02BX14

Pharmacological properties

Pharmacodynamics

Rebampid increases prostaglandin E2 (PGE2) content in gastric mucosa and increases PGE2 and GI2 content in gastric juice content. It has cytoprotective effect on the gastric mucosa under the damaging effects of ethanol, acids and alkalis, acetylsalicylic acid.

It promotes the activation of enzymes that accelerate the biosynthesis of high-molecular-weight glycoproteins, and increases the content of mucus on the surface of the gastric wall.

Helps improve the blood supply to the gastric mucosa, activates its barrier function, activates alkaline secretion of the stomach, increases the proliferation and metabolism of gastric epithelial cells, cleanses the mucosa of hydroxyl radicals and suppresses superoxides, produced by polymorphonuclear leukocytes and neutrophils in the presence of Helicobacter pylori, protects gastric mucosa from bacterial damage, has gastroprotective effect when the mucosa is affected by non-steroidal anti-inflammatory drugs (NSAIDs).

Pharmacokinetics

Absorption when taken orally is high. After administration at a dose of 100 mg, the peak plasma concentration (C_max) is reached after approximately 2 hours and is 340 ng/ml. The elimination half-life (T_1/2) is approximately 1.0 h. Repeated administration of the drug does not cause its cumulation in the body.

About 10% of the drug is excreted by the kidneys, mostly unchanged. When taken in a dose of 600 mg, traces of the hydroxylated metabolite can be excreted.

In in vitro experiments it has been shown that 98.4% to 98.6% of the drug is bound to plasma proteins.

Indications

Active ingredient

Composition

1 film-coated tablet contains:

The active substance: rebampid – 100 mg.

Auxiliary substances: magnesium carbonate, hypromellose (hydroxypropyl methylcellulose), collidone XL F, sodium lauryl sulfate, citric acid, magnesium stearate.

Auxiliary substances for the coating: hypromellose (hydroxypropyl methylcellulose), macrogol 6000 (polyethylene glycol 6000), titanium dioxide, talc.

How to take, the dosage

Interaction

Special Instructions

Impact on the ability to drive vehicles, mechanisms

The effect of the drug on the speed of psychomotor reactions and/or the ability to operate vehicles or mechanisms has not been studied. Driving and other activities requiring increased concentration should be treated with caution when taking the drug.

Synopsis

Contraindications

Individual intolerance to rebampide or other components of the drug.

Pregnancy.

Lactation period.

Children under 18 years of age.

Cautions

Cautions are recommended when first prescribing rebampide to elderly patients due to the possibility of hypersensitivity to the drug.

Side effects

Gastrointestinal tract: constipation, flatulence, diarrhea, nausea, vomiting, abdominal pain, taste disorders, heartburn.

Liver disorders: signs of liver dysfunction, increased serum glutamine alanine aminotransferase (ALT) and serum glutamine aspartate aminotransferase (AST).

Hematopoietic system disorders: leukopenia, granulocytopenia.

Allergic reactions: itching, skin rash, eczematous rash.

Other: menstrual disorders.

Overdose

Symptoms of rebamipide overdose are not described, no cases of intentional overdose have been reported to date. Nausea, vomiting, abdominal pain, diarrhea or constipation, headache are possible.

Care measures: A specific antidote is not known. In case of overdose, gastric lavage and symptomatic therapy should be carried out.

Pregnancy use

Similarities